Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Bardy Diagnostics, Dariohealth, Hillrom, Histosonics, Tada Medical.
DUBLIN – Inotrem SA has received €45 million (US$53 million) in public funding commitments to move its Trem-1 inhibitor, nangibotide, into a phase II/III trial in COVID-19 patients who are critically ill and on ventilation.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Beigene, Bluebird, Humanigen, Innovent, Lysogene.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Eurofins, Lazurite, J&J, Mission Bio, Quantumdx, Rite Aid, Sequanta Technologies.
The U.S. Securities and Exchange Commission (SEC) has had Parallax Health Sciences Inc. in its crosshairs at least as far back as April 2020, when the agency suspended trading of the company’s shares. In the latest development, the SEC charged the company and two of its executives with misleading investors regarding the availability of COVID-19 screening tests and personal protective equipment, actions the agency said were undertaken to exploit the pandemic in an effort to boost the company’s share prices.